Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term regimen. Found 8 abstracts

Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 2014 Apr;12(2):130-7.   PMCID: Pmc4142680
Landau H, Pandit-Taskar N, Hassoun H, Cohen A, Lesokhin A, Lendvai N, Drullinsky P, Schulman P, Jhanwar S, Hoover E, Bello C, Riedel E, Nimer SD, Comenzo RL. Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leukemia & lymphoma. 2012 Feb;53(2):275-81.
Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansar R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 2006 May;24(13):2038-43.
Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002 Jun 15;99(12):4336-42.
Meropol NJ, Sonnichsen DS, Birkhofer MJ, Ferreira I, Noel D. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Cancer Chemotherapy and Pharmacology. 1998 Mar;43(3):221-6.
Fields SZ, Igwemezie LN, Kaul S, Schacter LP, Schilder RJ, Litam PP, Himpler BS, McAleer C, Wright J, Barbhaiya RH, Langer CJ, Odwyer P. Phase I Study of Etoposide Phosphate (Etopophos) as a 30-Minute Infusion on Day-1, Day-3, and Day-5. Clinical Cancer Research. 1995 Jan;1(1):105-11.
Kaul S, Igwemezie LN, Stewart DJ, Fields SZ, Kosty M, Levithan N, Bukowski R, Gandara D, Goss G, Odwyer P, Schacter LP, Barbhaiya RH. Pharmacokinetics and Bioequivalence of Etoposide Following Intravenous Administration of Etoposide Phosphate and Etoposide in Patients with Solid Tumors. Journal of Clinical Oncology. 1995 Nov;13(11):2835-41.
Longo DL, Duffey PL, Jaffe ES, Raffeld M, Hubbard SM, Fisher RI, Wittes RE, Devita VT, Young RC. Diffuse Small Noncleaved-Cell, Non-Burkitts Lymphoma in Adults - a High-Grade Lymphoma Responsive to Promace-Based Combination Chemotherapy. Journal of Clinical Oncology. 1994 Oct;12(10):2153-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term regimen

Last updated on Wednesday, February 05, 2020